VolitionRX Ltd (NYSEAMERICAN:VNRX) Short Interest Update

Share on StockTwits

VolitionRX Ltd (NYSEAMERICAN:VNRX) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 61,000 shares, an increase of 11.1% from the June 30th total of 54,900 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 104,200 shares, the short-interest ratio is presently 0.6 days.

VNRX stock opened at $3.97 on Friday. VolitionRX has a 12-month low of $1.67 and a 12-month high of $4.65.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Monday, August 12th. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01.

In other VolitionRX news, Director Martin Charles Faulkes purchased 70,731 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were bought at an average price of $3.02 per share, for a total transaction of $213,607.62. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

A number of hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in VolitionRX in the first quarter valued at $35,000. Bank of New York Mellon Corp increased its stake in VolitionRX by 179.9% in the fourth quarter. Bank of New York Mellon Corp now owns 28,924 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 18,589 shares in the last quarter. Finally, Morgan Stanley increased its stake in VolitionRX by 15.4% in the second quarter. Morgan Stanley now owns 94,350 shares of the medical research company’s stock valued at $296,000 after purchasing an additional 12,600 shares in the last quarter.

VolitionRX Company Profile

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Recommended Story: Stock Symbol

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.